[Response judgement - conventional versus new methods].
New ways of evaluating treatment success among thoracic tumour patients are increasingly being used alongside more conventional methods. These new approaches include tumour regression grading, CAD volumetry (computer-assisted volumetry), determination of the tumour density and tumour perfusion as well as the use of positron emission tomography (PET) using 18F-FDG (fluorodeoxyglucose) or other tracers. Increasingly, endpoints that impact directly on the patient's quality of life and tumour-related symptoms are becoming more relevant factors together with the objectively measurable parameters used for assessing treatment response. This contribution describes the potential value of new methods and end-points from the point of view of a pathologist, radiologist, nuclear medicine specialist, radiotherapist, thoracic surgeon, medical and pneumology oncologist, and general practitioner.
Diederich
Stefan
S
Institut für Diagnostische und Interventionelle Radiologie, Marien-Hospital Düsseldorf, Deutschland.
Engeser
Peter
P
Junker
Klaus
K
Passlick
Bernward
B
Pfluger
Thomas
T
Pottgen
Christoph
C
Reck
Martin
M
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000175:diagnosis / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D017024:Chemotherapy, Adjuvant; D017326:Clinical Trials, Phase III as Topic; D003131:Combined Modality Therapy; D054893:Cone-Beam Computed Tomography; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008175:Lung Neoplasms / Q000175:diagnosis / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D008207:Lymphatic Metastasis / Q000473:pathology; D020360:Neoadjuvant Therapy; D009367:Neoplasm Staging; D010348:Patient Care Team; D049268:Positron-Emission Tomography; D011788:Quality of Life; D018714:Radiotherapy, Adjuvant; D016032:Randomized Controlled Trials as Topic; D012680:Sensitivity and Specificity; D015996:Survival Rate; D036542:Tomography, Spiral Computed; D016896:Treatment Outcome
D019788:Fluorodeoxyglucose F18